<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671307</url>
  </required_header>
  <id_info>
    <org_study_id>CBC101</org_study_id>
    <nct_id>NCT00671307</nct_id>
  </id_info>
  <brief_title>Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels</brief_title>
  <official_title>Phase 1b Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Critical Biologics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Critical Biologics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the pharmacokinetics and safety of an infusion of a single
      dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the
      Intensive Care Unit with documented low levels of natural gelsolin. It is believed that this
      drug will raise the gelsolin levels in these patients and decrease the probability that they
      will develop complications from their underlying disease such as organ system failure or
      death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, ascending single dose of
      rhu-pGelsolin infusion study. Thirteen subjects (10 active and 3 placebo) will be dosed at 3
      mg/kg and 5 subjects (3 active and 2 placebo) will be dosed at 6 mg/kg. In addition,
      twenty-two subjects (18 active and 4 placebo) will be dosed at 6 mg/kg per day for 3 days.
      The Data Safety Monitoring Committee (DSMC) and Steering Committee will review the preceding
      dose safety data, and agree the tolerability prior to the enrolment for next higher dose.
      Blood samples will be collected during 1 hour infusion through 72 hours post dose for PK
      assessment after each dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma gelsolin</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and the development of anti-rhu-pGelsolin antibodies</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of sepsis biomarkers</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (mortality, duration of ICU stay, duration of ventilator support, duration of hospital stay)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Low Gelsolin</condition>
  <condition>Trauma</condition>
  <condition>Infection</condition>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhu-pGelsolin</intervention_name>
    <description>IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid-dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Recombinant plasma gelsolin</other_name>
    <other_name>CBC-100</other_name>
    <other_name>Solinex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle control given as IV infusion over 1 hour</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age

          -  Documented gelsolin level &lt;100 mg/mL

          -  Admission to ICU

          -  Women of child-bearing age have a negative pregnancy test

          -  Multiple Organ Failure score &lt; 4

          -  Catheter present through which blood samples can be taken

          -  Written Informed Consent obtained

        Exclusion Criteria:

          -  Participation in other investigational treatment protocols

          -  Patients &lt;18 years of age

          -  Patients who have a modified Multiple Organ Failure score of &gt;=4

          -  Patient, who in the opinion of the Principal Investigator, are unlikely to be in the
             ICU for &gt;48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai M Chan, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Selene Tam, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Hong Kong; Clinical Trials Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard C Straube, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Critical Biologics Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital; University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>SAR</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007 Mar;35(3):849-55.</citation>
    <PMID>17205019</PMID>
  </reference>
  <reference>
    <citation>Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006 Mar;243(3):399-403.</citation>
    <PMID>16495706</PMID>
  </reference>
  <reference>
    <citation>Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med. 2002 Jan;50(1):54-60. doi: 10.2310/6650.2002.33518.</citation>
    <PMID>11813829</PMID>
  </reference>
  <reference>
    <citation>Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol (1985). 2004 Jan;96(1):25-31. Epub 2003 May 2.</citation>
    <PMID>12730154</PMID>
  </reference>
  <reference>
    <citation>Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1673-81.</citation>
    <PMID>10556139</PMID>
  </reference>
  <reference>
    <citation>DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002 Dec 15;100(13):4367-71. Epub 2002 Aug 1.</citation>
    <PMID>12393536</PMID>
  </reference>
  <reference>
    <citation>Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997 Apr;25(4):594-8.</citation>
    <PMID>9142022</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Richard Straube, MD/ Chief Medical Officer</name_title>
    <organization>Critical Biologics Corporation</organization>
  </responsible_party>
  <keyword>Gelsolin</keyword>
  <keyword>Trauma</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Peritonitis</keyword>
  <keyword>Burn</keyword>
  <keyword>Infection</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Systemic Inflammatory Response Syndrome</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

